On Sept. 14-16 more than 200 participants from across the country attended the 4th Annual Duke-Industry Statistics Symposium (DISS 2016) “Precision Medicine in Cancer Research.
The Symposium was expanded this year to three days. The first day included 6 separate short courses with topics ranging from adaptive designs to interim analysis to patient reported outcomes. Dr Lisa LaVange, Director of the Center for Drug Evaluation and Research, FDA, delivered the keynote address on Precision Medicine Initiatives at FDA. Her address followed brief remarks by Dr. Liz Delong, Chair of the Biostatistics and Bioinformatics Department, Dr. Eric Peterson, Executive Director of the Duke Clinical Research Institute, Terry Sosa of Quintiles and James Love of Boehringer-Ingelheim. The remainder of the morning and the final day included 17 parallel scientific sessions.
Prizes for best posters were awarded for Clinical Phenotyping Validation: Lessons Learned to Matthew Phelan of Duke Clinical Research Institute and for Dilemma On Conditional Power Based Sample Size Re-Estimation by Yi Tsong, Meiyu Shen, and Yu-Ting Weng, FDA and Xiaoyu Cai, George Washington University.
This symposium was organized by the Department of Biostatistics and Bioinformatics, Duke University School of Medicine and co-sponsored by Amgen, Boehringer-Ingelheim, ICSA, NC-ASA Chapter, Parexel, Quintiles and SAS. It was established 4 years ago to discuss challenging issues and recent advances related to the clinical development of drugs and devices and to promote research and collaboration among statisticians from industry, academia, and regulatory agencies.
